Biological
Vonicog alfa clinical trials
Also written VONVENDI, BAX 111 and TAK-577.
- studies test it
- 8
- open now
- 2
- in phase 3
- 8
- first study started
- 2011
Keep track of what changes. Save the vonicog alfa studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Other names
Studies by the year they started
8 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2019 | 2 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 1
Baxalta now part of Shire (4) · Takeda (3) · Margaret Ragni (1)
Often tested with
Tested in the same studies.
Antihemophilic factor, human recombinant (3) · F8 protein, human (3) · Tranexamic Acid (1)
Studies
Open first, then newest update. How each study uses vonicog alfa is read from its arms, and is right about nine times in ten.
Testing it · 8
- A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)RecruitingPhase 3TakedaNCT05582993Written as Vonicog Alfa
- A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)RecruitingPhase 3TakedaNCT07129343Written as VONVENDI
- A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)CompletedPhase 3Baxalta now part of ShireNCT02932618Written as Vonicog alfa
- A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)CompletedPhase 3Baxalta now part of ShireNCT03879135Written as rVWF
- Minimize Menorrhagia in Women With Von Willebrand DiseaseTerminatedPhase 3Margaret RagniNCT02606045Written as recombinant von Willebrand factor
- rVWF IN PROPHYLAXISCompletedPhase 3TakedaNCT02973087Written as von Willebrand factor (Recombinant)
- Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)CompletedPhase 3Baxalta now part of ShireNCT01410227Written as Recombinant von Willebrand factor (rVWF)
- Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing SurgeryCompletedPhase 3Baxalta now part of ShireNCT02283268Written as Recombinant von Willebrand Factor (rVWF)
Codes
What other systems call vonicog alfa · ClinicalTrials.gg INT015103
- UNII (FDA) 5PKM8P0G5IVONICOG ALFAConfirmed FDA, Wikidata
- RxNorm 1812589Confirmed FDA, Wikidata
- Wikidata Q96414099vonicog alfaConfirmed FDA, Wikidata
- NCI Thesaurus C152910Vonicog AlfaOne source FDA
- DrugBank DB12872One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5PKM8P0G5I | VONICOG ALFA | Confirmed FDA, Wikidata |
| RxNorm | 1812589 | — | Confirmed FDA, Wikidata |
| Wikidata | Q96414099 | vonicog alfa | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152910 | Vonicog Alfa | One source FDA |
| DrugBank | DB12872 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.